copper-64/67 based theranostic pair targeting CA19-9 (Clarity Pharmaceuticals/Memorial Sloan Kettering Cancer Center)

N/A

Report date: 2025/10/28 16:07:00

Base Information

Drug Namecopper-64/67 based theranostic pair targeting CA19-9 (Clarity Pharmaceuticals/Memorial Sloan Kettering Cancer Center)
Drug Alias Name[64Cu]-SAR-5B1 + [67Cu]-SAR-5B1copper-64Cu-SAR-5B1 + copper-67-SAR-5B1SAR-5B1-[64Cu] + SAR-5B1-[67Cu]
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agent +[7] 
Mechanisms of ActionPositron-emission tomography enhancers
TargetsUpdating
Therapy Area/IndicationsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterClarity Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A